Background-Endoscopic ultrasonography (EUS) and somatostatin receptor scintigraphy (SRS) can detect a high percentage of gastroenteropancreatic neuroendocrine tumours especially in the upper gastrointestinal tract. The ability of these procedures to localise primary tumour lesions and metastases of gastrinomas and insulinomas was evaluated in comparison with transabdominal ultrasonography (US), computed tomography (CT) and magnetic resonance imaging (MRI) . Patients and Methods-In a prospective trial, patients with gastrinomas (n=10) and insulinomas (n=10) diagnosed by clinical signs and laboratory tests were assessed by EUS, SRS, US, CT and MRI. Results-In 10 patients with gastrinoma and 10 patients with insulinoma, a total of 14 separate primary tumour lesions were histologically confirmed for each of the tumour entities. The mean diameter was 2-1 cm for gastrinomas and 1l5 cm for insulinomas. All insulinomas and nine gastrinoma lesions were located in the pancreas. Three gastrinomas were found in the duodenal wall, one in a periduodenal lymph node, and one in the liver. For gastrinomas, sensitivities were 79% with EUS, 86% with SRS and 29% with CT, US, and MRI. For insulinomas, sensitivities were 93% with EUS, 14% with SRS, 21% with CT and 7% with US and
Insulinomas and gastrinomas, defined as functional neuroendocrine tumours of the upper gastrointestinal tract, become clinically manifest by characteristic symptoms and are confirmed by specific laboratory tests (fasting test, secretin test). The treatment of choice is surgical removal of the tumour.' 2 It is difficult to preoperatively localise the primary tumour or to determine the extent of the disease, especially lymph node involvement and distant metastases. Preoperative localisation with noninvasive imaging techniques such as computed tomography (CT), transabdominal ultrasound (US) and magnetic resonance imaging (MRI) is only successful in 30-60% of cases. 3 In particular, tumours smaller than 2 cm in diameter and those located within the gastrointestinal wall escape detection in almost all cases. 6 More invasive localisation procedures such as angiography, transhepatic portal venous blood sampling and exploratory laparotomy, including endoscopic transillumination and intraoperative ultrasound, have been successfully applied in over 90% of cases. [7] [8] [9] [10] The commonly benign insulinomas with mostly solitary and solely intrapancreatic occurrence are generally difficult to localise because they are usually less than 2 cm in size." Preoperative diagnostic assessment of gastrinomas is equally problematic. Gastrin secreting neuroendocrine tumours are extrapancreatic in 50% of cases, small -especially in the duodenal wall -often multilocular, and metastatic in about half of the cases.'2 13 Apart from localisation of the primary tumour, detection of local tumour infiltration, lymph node involvement, and metastases is of great importance before surgical removal.
Visualisation of the pancreas as well as the intestinal wall and its immediate surroundings can be achieved by endoscopic ultrasound (EUS) with very high resolution. Pathological structures up to 2-3 mm in size can be detected. Several mainly retrospective studies have shown that EUS is a highly sensitive imaging procedure for pancreatic endocrine tumours, detecting 80-90% of the lesions. '4-17 Prospective studies also showed high sensitivities for EUS in the localisation of insulinomas and intrapancreatic gastrinomas, whereas extrapancreatic gastrinomas could be localised with lower sensitivities. ' Ulcer  726  624  628  473  2  42  F  Ulcer  596  298  295  212  3  8  F   Ulcer/Diarrhoea   976  311  1123  476  4  37  M  Ulcer  98  412  <20  246  <20  246  <20  43  5  30  F  Ulcer  674  512  96  131  6  38  F  Ulcer  1123  476  <20  78  7  62  M  Diarrhoea  20  441  <20  15  8  80  F  Ulcer  327  276  411  293  9  60  M  Ulcer  236  448  <20  78  10  61  M  Ulcer  142  327  134  53 Normal serum gastrin value < 150 pg/ml. Normal secretin test if increase of gastrin <200 pg/ml.
partly without comparison to surgical findings. Because a direct comparison between SRS and EUS was also lacking, we have carried out a prospective comparative study on the value of EUS, SRS, CT, US, and MRI in the diagnostic assessment of insulinomas and gastrinomas with reference to the final surgical findings.
Methods
Twenty patients (14 female, 6 male, mean age 52 (range 8-82) years) with insulinomas (n= 10) or gastrinomas (n= 10) were prospectively examined by EUS, SRS, US, CT, and MRI from March 1991 until December 1994 (Table I and II) . All patients were screened for hyperparathyroidism by determination of (Table II ). In 10 of 10 patients with gastrinoma and eight of 10 patients with insulinoma, the diagnosis was confirmed histologically and immunohistologically after surgery (Tables III and V) . Immunohistological examination was carried out with antibodies against chromogranin A, synaptophysin, neuron specific enolase, insulin, gastrin, somatostatin, and serotonin. In two of 10 patients with insulinoma the primary lesion was histologically confirmed by CT or US guided puncture (Table V) . One female patient with insulinoma had a multiple endocrine neoplasia, type 1 (MEN I) ( Table V) . Intraoperative ultrasonography was performed in all patients operated on. Duodenal transilluminations were done in all patients with gastrinoma. However, these two methods were not included for evaluation in our study protocol. Endoscopic ultrasound examinations were carried out with echoendoscopes, using an ultrasound frequency of 7.5 or 12 MHz and scanning in a plane perpendicular to the shaft axis of the endoscope (GF-UM 3/20, Olympus). The transabdominal ultrasound examinations were carried out with mechanical sector scanners and a sound frequency of 3-5 or 5 MHz (LSC 7000, Picker). CT examinations were performed after oral and intravenous bolus contrast application (Somatom DRH, Siemens). The total abdomen was examined in 8 mm and the pancreatic region in 4 mm planes. Examinations with MRI were carried out with a 1.5 Tesla (Magnetom GBSII, Siemens) in 8 mm thick transverse sections using three pulse sequences. A Ti weighted (SE 500/15), a T2 weighted (SE 2.300/90) and a fast TI weighted (GRE 160/5/800) spin echo sequence were used. The SRS examinations were carried out after an intravenous bolus of 100-200 Mbq l`lIn labelled pentetreotide (Octreoscan 111 Mallinckrodt-Diagnostica, Petten, Holland). Planar images were recorded with a large field view gammacamera (Orbiter 7500; Siemens, Erlangen, Germany) equipped with a 360 KeV parallel hole collimator. All patients underwent anterior and posterior whole body static scintigraphy. Planar images were obtained four, 24 , and in selected cases, 48 hours after injection of the radioligand. Single-photon emission computed tomography (SPECT) (3600 rotation in 32 minutes, matrix 64X64) was performed 24 hours after injection using a Sopha DS 7 camera (Sopha Medical, Frankfurt am Main, Germany) with a medium energy parallel hole general purpose collimator; images were reconstructed with filtered back projection and Chang correction in 6.7 mm slices. Digital (planar) images were analysed quantitatively by the region of interest method. Data were not corrected for transmission absorption or self attenuation. Liver uptake was calculated from the anterior view, and that of the spleen and kidneys were calculated from the posterior view. This technique has previously been described in detail.6 26 
Results

GASTRINOMAS
A total of 14 separate primary tumour lesions were histologically confirmed in 10 patients (Table III) . Nine tumours were situated in the pancreas (head n=7, body n= 1, tail n= 1), three in the duodenal wall, one in a periduodenal lymph node, and one in the liver (Table III) . None of the patients with gastrinoma showed evidence of MEN I. Four patients had two gastrinoma lesions each. The mean tumour diameter was 2-1 cm. Four patients had a malignant tumour, with infiltration of the portal vein (n= 1), the superior mesenteric vein (n=1), and liver metastases (n=2) ( Table III) . Twelve of 14 tumours (sensitivity 86%) could be visualised with SRS. Eleven of 14 tumours could be localised by EUS (sensitivity 79%) and four of 13 by US (sensitivity 29%) as well as by CT and MRI (Tables III and IV) . A gastrinoma (4 cm in diameter) at the duodenojejunal flexure, a 2-4 cm tumour in the pancreatic head, and a 1.2 cm tumour in a periduodenal lymph node were not detected by EUS (Table III) . The smallest tumours visualised by EUS were an 8 mm tumour of the duodenal wall and a 5 mm tumour in the pancreatic head (Table III) . Ten of 14 gastrinoma lesions (71%) were identified only by EUS and SRS (Table III) . The tumours not detected by SRS were a 5 mm lesion situated in the pancreatic head and a 1.2 cm periduodenal tumour (Table III) . The liver metastases in two patients were only correctly detected by SRS. In both patients, only SRS disclosed an increased local hepatic uptake of pentetreotide. These metastases could not be detected at the first operation by either surgical palpation or intraoperative ultrasound. However, postoperatively increasing gastrin values and positive secretin tests together with positive SRS findings led to second surgical interventions six and 18 months after the first operation. Intraoperative uiLiasound and palpation confirmed the initial SRS findings in both patients. In one case, intraoperatively detected multiple (>20) small (<1 cm) metastases in both liver lobes were not resectable. In the second case, two metastases of the left liver lobe were resected.
Intraoperatively, two patients showed tumours infiltrating the portal vein in one case and the superior mesenteric vein in the other (Table III) . Preoperatively, these infiltrations could not be detected by any of the evaluated procedures or by angiography. A complete resection of the tumour was not achieved in either case.
Postoperatively, five patients had normalised fasting serum gastrin concentrations and a negative secretin test. Also, follow up by SRS, EUS, CT, MRI, and US showed no evidence of recurrence. Thus a curative resection was possible in five of 10 patients. Elevated fasting serum gastrin concentrations or a positive secretin test were found in the two patients with liver metastases as well as in two others with non-resectable pancreatic head tumours infiltrating the portal and superior mesenteric veins (Table III) . In the patient with a solitary liver tumour, elevated gastrin concentrations were still found postoperatively. However, no other tumour lesions were found during the operation by either surgical palpation, intraoperative ultrasound, or duodenal transillumination.
The visualised duodenal tumours were endosonographically restricted to the middle hyperechoic layer (submucosal layer; Fig IA) . Endosonographically, eight of the 1 1 visualised gastrinomas displayed a hypoechoic (compared with the pancreas parenchyma), a homogeneous inner structure, and a smooth delineation (Fig iB) . Only three gastrinomas with a tumour diameter of more than 3 cm had an inhomogeneous, hyperechoic inner structure with hypoechoic to non-echoic parts and were irregularly demarcated. On SRS, gastrinoma lesions displayed a pronounced accumulation of radiolabelled somatostatin receptor ligand in all cases (Fig 1 C) .
INSULINOMAS
Fourteen neuroendocrine tumour lesions were histologically verified in 10 patients thought to have an insulinoma (Table V) . All tumours were intrapancreatic. The mean tumour diameter was 1.5 cm. Two female patients had a malignant insulinoma with liver metastases. The primary lesion as well as the liver metastases of these two patients could be confirmed by biopsy. Angiography disclosed a primary tumour lesion infiltrating the splenic vein in one of these patients. In one patient with evidence of MEN I, five tumours were surgically confirmed (Table V) .
The location of 13 of 14 tumours could be visualised using EUS (sensitivity 93%). Only two of 14 tumours could be localised by SRS (sensitivity 14%), three of 14 by CT (sensitivity 21%), one of 14 by US (sensitivity 7%), and one of 14 by MRI (sensitivity 7%) (Tables   IV and V) . Only one tumour, 8 mm in diameter, in a patient with MEN I, was not detected using EUS. This tumour was situated in the cranial part of the pancreatic tail (Table  V) . The other four tumour lesions of this patient, also located in the pancreatic tail, and an additional adenoma of the adrenal gland were clearly detected by EUS. Eight of 14 insulinoma lesions (57%) could only be localised by EUS (Table V) . The liver metastases confirmed in two female patients had been detected in both cases by CT, US, and MRI, in one case by SRS and in neither case by EUS. It is noteworthy that one patient with a positive scintigraphic finding of liver metastases had a negative SRS finding with regard to the intrapancreatic primary tumour. Additional infiltration of the splenic vein in one of the patients with liver metastases was detected by EUS and US but not by CT and MRI. The eight patients with insulinoma who underwent surgery no longer had hypoglycaemia postoperatively, and their fasting tests were normal.
Endosonographically, 11 of 13 visualised insulinomas displayed a hypoechoic (compared to the pancreas parenchyma), homogeneous inner structure and mostly a smooth delineation (Fig 2A) . One of these 1 1 tumours, infiltrating the splenic vein, and two others in the patient with MEN I, were irregularly demarcated. Two other patients with benign insulinomas had hyperechoic tumours.
Discussion
This prospective study evaluated the accuracy of EUS and SRS compared with conventional imaging procedures in diagnosing insulinomas and gastrinomas. Most of the detected tumours were located in the pancreas. All tumours were histologically confirmed.
Regarding tumour size and location, our patients with surgically and histologically confirmed insulinomas showed no essential differences from those in other studies, whereas our gastrinoma population had fewer extrapancreatic tumours than the patients of previous studies. '8 19 These studies also examined the value of imaging procedures in the diagnostic assessment of insulinomas and gastrinomasi3 4 In summary, our data show that EUS has the highest sensitivity for both tumour entities, whereas SRS has a comparable sensitivity only in the case of gastrinomas. On the other hand CT, US, and MRI are good imaging procedures only for the determination of metastatic spread.
For gastrinomas, SRS and EUS represent the methods of choice for preoperative diagnosis. A combination ofboth methods achieves a reliability comparable with that of invasive operative procedures for the identification of both primary and secondary lesions. SRS has a direct therapeutic impact because it is able to detect metastases equally well. To exclude small gastrinomas in the duodenal wall or peripancreatic lymph nodes, intraoperative ultrasound and duodenal transillumination should always be performed as well as palpation during surgery.
The most sensitive diagnostic procedure for insulinomas was EUS. Here SRS is even less sensitive than US, CT, and MRI.
The use of US, CT, and MRI remains limited mainly to the identification of enlarged lymph nodes and liver metastases. 
